Stockscreener 앱 받기
35.10
2.12%
0.73
Guardant Health Inc 주식(GH)의 최신 뉴스
KAS Team Wins $292.5 Million In Jury Trial of Guardant Health v. Natera - Morningstar
Advantage Alpha Capital Partners LP Buys New Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo Finance
Jury Awards Guardant Health $292.5M in False-Advertising Lawsuit Against Natera - MarketWatch
Guardant says jury unanimously found in favor of company in Natera suit - TipRanks
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims - MSN
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update) - MSN
Guardant Health Wins Historic $292.5M False Advertising Verdict Against Natera | NTRA Stock News - StockTitan
Natera Plans Appeal After Guardant Health Lawsuit Verdict, Defends Signatera Test Leadership | NTRA Stock News - StockTitan
BREAKING: Jury Finds Natera Owes Guardant $292.5M In False Ad Suit - Law360
Landscape Capital Management L.L.C. Acquires Shares of 31,448 Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health, Inc. (GH): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
(GH) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Natera's Conduct 'Despicable,' Guardant Says As Trial Wraps - Law360
Guardant Health (GH) Set To Dominate The Growing Liquid Biopsy Market - Insider Monkey
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
GH (Guardant Health) Operating Cash Flow per Share : $-2.10 (TTM As of Sep. 2024) - GuruFocus.com
Guardant Health Stock Sees RS Rating Jump To 83 - Yahoo! Voices
Guardant Health: Focused On Future Growth, Hold - Seeking Alpha
GH (Guardant Health) Free Cash Flow per Share : $-2.26 (TTM As of Sep. 2024) - GuruFocus.com
Guardant Health, Inc. (NASDAQ:GH) Q3 2024 Earnings Call Transcript - MSN
Guardant Health CIO Kumud Kalia sells $204,722 in stock - Investing.com India
Guardant Health Inc (GH) Shares Up 5.46% on Nov 19 - GuruFocus.com
Sumitomo Mitsui Trust Group Inc. Grows Stake in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health (FRA:5GH) Total Inventories : €65.1 Mil (As of Sep. 2024) - GuruFocus.com
Natera Exec Calls Guardant's Cancer Test Claims 'Dangerous' - Law360
Insider Selling: Director Meghan Joyce Sells Shares of Guardant Health Inc (GH) - GuruFocus.com
Guardant Health director Meghan Joyce sells $86,595 in stock - Investing.com
CADIAN CAPITAL MANAGEMENT, LP's Strategic Acquisition in Guardan - GuruFocus.com
Guardant Atty Accuses Natera CEO Of Dishonesty At Trial - Law360
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Baillie Gifford & Co. - MarketBeat
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market - openPR
Guardant Health Inc (GH) Stock Price Up 6.63% on Nov 13 - GuruFocus.com
Guardant CEO Says Rival's False Ads Hurt 'Beautiful Baby' - Law360
Multi-cancer Early Detection Market Next Big Thing| Major Giants Exact Sciences, AnchorDx, Guardant Health - openPR
Wellington Management Group LLP Bolsters Stake in Guardant Healt - GuruFocus.com
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher - Simply Wall St
Guardant Health, Inc. (NASDAQ:GH) Shares Bought by ARK Investment Management LLC - MarketBeat
Guardant Health Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Why Guardant Health Stock Blasted 13% Higher on Thursday - MSN
Ex-Natera VP Defends Ad Campaign Against Rival Guardant - Law360
Guardant Health (GH) Stock Surges on Strong Q3 Earnings - GuruFocus.com
Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop - Yahoo! Voices
Leerink stays bullish on Guardant Health stock, citing robust growth prospects - Investing.com Canada
JPMorgan Chase & Co. Raises Guardant Health (NASDAQ:GH) Price Target to $50.00 - MarketBeat
Guardant Health (NASDAQ:GH) Shares Gap Up Following Analyst Upgrade - MarketBeat
Guardant Health (NASDAQ:GH) Price Target Raised to $36.00 at The Goldman Sachs Group - MarketBeat
Guardant Health Inc (GH) Trading 13.31% Higher on Nov 7 - GuruFocus.com
Guardant Health Inc (GH) Q3 2024 Earnings Call Highlights: Recor - GuruFocus.com
Guardant Health Inc (GH) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Guardant Health Inc (GH) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance - BioSpace
Natera Declared 'War' On Guardant, Jury Told At Trial's Start - Law360
1.43%
0.41%
자본화:
|
볼륨(24시간):